Mirza Mansoor Raza, a director at Sera Prognostics Inc. (NASDAQ:SERA), recently sold a portion of his holdings in the company. According to a recent SEC filing, Raza sold 95 shares of Sera Prognostics' Class A common stock on November 11, 2024. The shares were sold at a weighted average price of $7.32, resulting in a total transaction value of approximately $695.
The sale was conducted as part of a "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units. This type of transaction is mandated by the company's policy and does not reflect a discretionary decision by Raza. Following this transaction, Raza holds 6,729 shares of Sera Prognostics directly.
In other recent news, Sera Prognostics reported its Q3 financials, revealing a decrease in net revenue from $42,000 to $29,000 compared to the same quarter in the previous year. This comes alongside an 8% increase in operating expenses to $8.9 million and a 10% rise in net loss, now standing at $7.9 million. Despite these financial challenges, the company has been focusing on promoting its PreTRM test, designed to improve maternal health outcomes. This effort includes a TV campaign and an online ordering system for home delivery.
Sera Prognostics also reported a significant surge in website traffic, up by 227% due to increased accessibility and educational campaigns. The company maintains a strong cash position, with $74.3 million in cash and equivalents, projected to sustain operations until 2027. The firm is eagerly anticipating the publication of the PRIME study results, which are expected to influence clinical guidelines and payer support, key factors in the company's future growth. These recent developments highlight Sera Prognostics' commitment to advancing maternal health and securing its financial stability.
InvestingPro Insights
To provide additional context to Mirza Mansoor Raza's recent stock sale, it's worth examining some key financial metrics and insights from InvestingPro for Sera Prognostics Inc. (NASDAQ:SERA).
According to InvestingPro data, Sera Prognostics has a market capitalization of $244.51 million USD. Despite the recent insider sale, the company's stock has shown impressive performance over the past year, with a one-year price total return of 340.24% as of the latest data.
However, investors should note that Sera Prognostics is currently not profitable, with a negative P/E ratio of -7.35 over the last twelve months as of Q3 2024. This aligns with an InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
Another relevant InvestingPro Tip highlights that Sera Prognostics holds more cash than debt on its balance sheet. This strong liquidity position could provide the company with financial flexibility as it works towards profitability.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights. In fact, there are 8 more InvestingPro Tips available for Sera Prognostics, which could provide valuable context for understanding the company's financial position and future prospects.
Mirza Mansoor Raza, a director at Sera Prognostics Inc. (NASDAQ:SERA), recently sold a portion of his holdings in the company. According to a recent SEC filing, Raza sold 95 shares of Sera Prognostics' Class A common stock on November 11, 2024. The shares were sold at a weighted average price of $7.32, resulting in a total transaction value of approximately $695.
The sale was conducted as part of a "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units. This type of transaction is mandated by the company's policy and does not reflect a discretionary decision by Raza. Following this transaction, Raza holds 6,729 shares of Sera Prognostics directly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.